CDKN2A and oropharynx cancer: In our results, we observed that OPSCC patients with p16 overexpression had significantly longer disease-specific survival than p16 negative patients following surgery as well as postoperative adjuvant radiotherapy, which was consistence with published data about the potential prognostic maker of p16 in oropharyngeal cancer.